BACKGROUND: Intracystic papillary carcinoma (IPC) is an uncommon breast neoplasm. To the authors' knowledge there are limited data regarding its epidemiology and only small studies focusing on outcomes. By using a large, population-based database, this study aimed to identify specific characteristics of patients with IPC, investigate its natural history, and determine its long-term prognosis. METHODS: The California Cancer Registry (CCR), a population-based registry, was reviewed from the years 1988 through 2005. The data were analyzed with regard to patient sex, age at presentation, tumor stage, and overall survival. Cumulative relative actuarial survival was determined using a Berkson-Gage life table method. The CCR classifies IPC as either in situ (CIS) or invasive, as determined by the local pathologist. RESULTS: A total of 917 cases of IPC were identified. Approximately 47% of cases (n = 427) were CIS, whereas 53% of cases had invasion (n = 490). The majority of the invasive cases were localized at the time of diagnosis (89.6%; n = 439). At 10 years, patients with CIS and invasive disease had a similar relative cumulative survival (96.8% and 94.4%; P = .18). CONCLUSIONS: IPC is a rare disease. There is no apparently significant difference in the long-term survival of patients in the 2 histologically derived subgroups of IPC. There is an excellent prognosis for patients diagnosed with IPC regardless of whether the tumor is diagnosed as in situ or invasive. Clinicians should keep this in mind when planning surgical and adjuvant treatments. Sentinel lymph node biopsy may be a prudent way to evaluate axillary involvement in patients with IPC. (c) 2008 American Cancer Society.
BACKGROUND:Intracystic papillary carcinoma (IPC) is an uncommon breast neoplasm. To the authors' knowledge there are limited data regarding its epidemiology and only small studies focusing on outcomes. By using a large, population-based database, this study aimed to identify specific characteristics of patients with IPC, investigate its natural history, and determine its long-term prognosis. METHODS: The California Cancer Registry (CCR), a population-based registry, was reviewed from the years 1988 through 2005. The data were analyzed with regard to patient sex, age at presentation, tumor stage, and overall survival. Cumulative relative actuarial survival was determined using a Berkson-Gage life table method. The CCR classifies IPC as either in situ (CIS) or invasive, as determined by the local pathologist. RESULTS: A total of 917 cases of IPC were identified. Approximately 47% of cases (n = 427) were CIS, whereas 53% of cases had invasion (n = 490). The majority of the invasive cases were localized at the time of diagnosis (89.6%; n = 439). At 10 years, patients with CIS and invasive disease had a similar relative cumulative survival (96.8% and 94.4%; P = .18). CONCLUSIONS: IPC is a rare disease. There is no apparently significant difference in the long-term survival of patients in the 2 histologically derived subgroups of IPC. There is an excellent prognosis for patients diagnosed with IPC regardless of whether the tumor is diagnosed as in situ or invasive. Clinicians should keep this in mind when planning surgical and adjuvant treatments. Sentinel lymph node biopsy may be a prudent way to evaluate axillary involvement in patients with IPC. (c) 2008 American Cancer Society.
Authors: Carmen C Solorzano; Lavinia P Middleton; Kelly K Hunt; Nadeem Mirza; Funda Meric; Henry M Kuerer; Merrick I Ross; Frederick C Ames; Barry W Feig; Raphael E Pollock; S Eva Singletary; Gildy Babiera Journal: Am J Surg Date: 2002-10 Impact factor: 2.565
Authors: N Q Mirza; G Vlastos; F Meric; A A Sahin; S E Singletary; L A Newman; H M Kuerer; F C Ames; M I Ross; B W Feig; R E Pollock; T A Buchholz; M D McNeese; E A Strom; G N Hortobagyi; K K Hunt Journal: Ann Surg Oncol Date: 2000-10 Impact factor: 5.344
Authors: Catherine M Sanders; Sidney L Saltzstein; Matthew M Schultzel; Duy H Nguyen; Helen Shi Stafford; Georgia Robins Sadler Journal: J Cancer Educ Date: 2012-12 Impact factor: 2.037
Authors: Meltem Baykara; Ugur Coskun; Umut Demirci; Ramazan Yildiz; Mustafa Benekli; Asli Cakir; Suleyman Buyukberber Journal: Med Oncol Date: 2009-08-13 Impact factor: 3.064
Authors: Sumanta Kumar Pal; Sean K Lau; Laura Kruper; Uzoamaka Nwoye; Carlos Garberoglio; Ravi K Gupta; Benjamin Paz; Lalit Vora; Eduardo Guzman; Avo Artinyan; George Somlo Journal: Breast Cancer Res Treat Date: 2010-06-04 Impact factor: 4.872
Authors: Enver İlhan; Orhan Üreyen; Abdullah Şenlikci; Ayşe Yağcı; Eyüp Yeldan; Tarık Salman; Mehmet Tahsin Tekeli Journal: J Breast Health Date: 2015-01-01